A Phase 2 interventional study of Placebo and Tarperprumig in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 57 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
157 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 75 are open to participants now.
This study's enrollment of 78 is above the median of 34 across 116 interventional studies indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered tarperprumig dose regimen #1 or dose regimen #2.
Drug: Tarperprumig
Participants will be administered tarperprumig dose regimen #1 or dose regimen #2.
Drug: Placebo · Drug: Tarperprumig
Participants will be administered placebo.
Drug: Placebo
Participants will receive placebo.
Participants will receive tarperprumig.
Also known as: ALXN1820
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline through Week 70
Number of Participants Achieving Disease Remission at Week 26
Time frame: Week 26
Number of Participants Achieving Sustained Remission at Week 52
Time frame: Week 52
Number of Participants Achieving a Birmingham Vasculitis Activity Score (BVAS) of 0
Time frame: Baseline through Week 52
Number of Participants Experiencing a Relapse After Previously Achieving Disease Remission at Week 26
Time frame: Week 26 through Week 70
Time to First Relapse After Having Achieved Disease Remission at Week 26
Time frame: Week 26 through Week 70
Change from Baseline in Vasculitis Damage Index
Time frame: Baseline, Weeks 26, and 52
Time to First Occurrence of BVAS of 0
Time frame: Baseline through Week 52
Change from Baseline in BVAS
Time frame: Baseline, Weeks 26, and 52
Change from Baseline in Estimated Glomerular Filtration Rate
Time frame: Baseline, Weeks 26, and 52
Change from Baseline in Proteinuria Based on Spot Urine Protein-Creatinine Ratio
Time frame: Baseline, Weeks 26, and 52
Change from Baseline in Proteinuria Based on Spot Urine Albumin-Creatinine Ratio
Time frame: Baseline, Weeks 26, and 52
Change from Baseline in Hematuria
Time frame: Baseline, Weeks 26, and 52
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tarperprumig
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis →
Alexion Pharmaceuticals, Inc. →